Several agents have been developed to target these molecules including the tyrosine kinase inhibitor imatinib, which induces clinical responses in gastrointestinal stromal tumors that harbour KIT mutations [4], and erlotinib and gefitinib which are effective in non-small cell lung cancers with mutations or insertions/deletions in EGFR [2, 5]. This evidence concerns the gene KIT and non-small cell lung carcinoma.